DNA vaccination against HER-2/neu is an effective way to induce an immune response able to oppose the spontaneous development of mammary tumours occurring in HER-2/neu transgenic mice. In this study, we have evaluated the potential of Imiquimod and the analogue S-27609 as adjuvants of DNA vaccination against HER-2/neu in transgenic mice. The association of a DNA vaccine encoding a portion of rat HER2/neu with either Imiquimod or S-27609 was found to delay the development of spontaneous mammary tumours and to reduce their incidence, in comparison with DNA vaccination alone. Almost 80 or 40% of tumour-free mice were found at the end of measurement time in mice vaccinated and supplemented with Imiquimod or S-27609, respectively. The antitumour preventive effect was associated with increased antibody and cell-mediated immune responsiveness against HER-2/neu. In mice vaccinated and supplemented with Imiquimod, a small but significant increase of rat p185 neu -specific cytotoxicity and of IFN-g and IL-2-producing CD8T cells, together with a reduction of IL-4-producing CD4T cells, and a switch from an IgG1 towards a IgG2a phenotype of anti-p185 neu antibodies, suggested a TH1 polarization of the immune response. The immunoregulatory efficacy of S-27609 was lower than that observed for Imiquimod. These data highlight the potential of Imiquimod, and, to a lower extent, of S-27609, as immunological adjuvants of therapeutic DNA vaccines.
Introduction
HER2/neu oncoprotein is a Tyr-kinase receptor, which is involved in cellular proliferation and differentiation. 1 HER2/neu is correlated to mammary carcinogenesis and its overexpression, observed in several human carcinomas, is associated with an aggressive disease and is a predictor of poor prognosis. 2 The intimate correlation between HER2/neu and neoplastic development and the typical transmembrane structure of this protein, which renders it easily accessible to the immune effectors, are both reasons that make this receptor an optimal target of antitumoral immunotherapies. Although HER2/neu is a self-antigen, a natural HER2/neu-specific immunity has been detected in HER2/neu-positive tumour patients; this immune response has been shown to be weak, but it demonstrates that tolerance to the oncoprotein is not complete and that appropriate schemes of immunization could amplify HER2/neu immunogenicity. 3 Several strategies against HER2/neu have been proposed and DNA vaccination represents an optimal methodology for activating the immune system against HER2/neu. 4 Various studies, some of which were carried out by our group, confirmed the possibility of inducing HER2/neu-specific immunity in HER2/neu transgenic mice by DNA vaccination with plasmids encoding fulllength or truncated HER2/neu. [5] [6] [7] [8] [9] In the investigated models, DNA vaccination inhibited tumour development according to vaccine properties; the use of molecules playing critical regulatory and signalling roles in immunity, such as immunomodulatory cytokines and costimulatory molecules, increased the effectiveness of DNA vaccines in terms of tumour prevention. 5, [10] [11] [12] [13] The use of these molecules as adjuvants in association with DNA vaccines has been found to enhance the specific immune response elicited by DNA immunization, resulting in augmentation of antigen-specific humoral and/or cell-mediated immune responses.
Imiquimod is an immune response modifier of the imidazo-quinoline family that has been demonstrated to exert profound antiviral and antitumour effects. 14 The immune-modulating properties of Imiquimod have been found to be exerted via the stimulation of endogenous cytokine production with consequent activation of the innate immune response as well as the cellular arm of acquired immunity. 15 It has been recently demonstrated that the immune-modulating effect of Imiquimod is in part due to its capacity to bind to and stimulate the toll-like receptor (TLR)-7 and TLR-8, thereby suggesting the potential role of Imiquimod and related compounds to act as adjuvants across a broad range of vaccination strategies. 16, 17 A recent investigation has shown the effectiveness of Imiquimod and its derivative resiquimod in inducing immune responses to immunization using a plasmid DNA-encoding chicken ovalbumin. 18 The aim of this study was to evaluate the potential of Imiquimod and the related compound S-27609 as adjuvants in association with an HER2/neu DNA vaccine in a transgenic murine model of HER2/neupositive mammary carcinoma (FVB/neuT transgenic mice). To perform this study, Imiquimod and S-27609 were administered to FVB/neuT mice in association with a plasmid vaccine encoding the extracellular and transmembrane HER2/neu domains; the antitumour effect and the immune response elicited by this vaccination strategy were then analysed.
Results
Effect of Imiquimod and S-27609 on the kinetics of tumour growth Figures 1 and 2 report the kinetics of spontaneous mammary tumour growth in mice treated with Imiquimod or S-27609 alone, or in addition to immunization with plasmid DNA encoding the extracellular and transmembrane domains of HER-2/neu (pNeuECDTM). Both figures report the data from the same group of experiments, shown in two separate graphs for a clearer presentation. As shown in Figure 1 (top), the treatment with Imiquimod alone was not able to delay the appearance of the first mammary tumour compared to control mice. In both groups, mammary carcinomas appeared at 25-27 weeks of age with all mice bearing one or more tumour masses at 40 weeks of age. The immunization of mice with the plasmid vaccine pNeuECDTM resulted in a slower kinetic of tumour incidence in comparison with control mice (Po0.001), with 12.5% of tumour-free mice at 40 weeks of age. Plasmid DNA pNeuECDTM, given in association with Imiquimod, delayed the appearance of mammary carcinomas (from 27 to 33 weeks) in HER2/neu transgenic mice. The adjuvant effect of Imiquimod on pNeuECDTM vaccine was particularly evidenced by the fact that almost 80% of animals were still free of tumours at 40 weeks of age (P ¼ 0.01). Figure 2 (top) describes the results obtained by the use of S-27609 as an adjuvant of pNeuECDTM DNA vaccine. As observed for Imiquimod, S-27609 alone did not influence the kinetics of tumour growth, whereas S-27609, given in association with the vaccine, proved to be more efficacious than the vaccine administered alone, even if the adjuvant properties of S-27609 were less remarkable than those of Imiquimod. In mice vaccinated and treated with S-27609, the appearance of mammary tumours was delayed from 25 to 31 weeks of age in comparison with mice vaccinated with the plasmid alone. At 40 weeks, almost 40% of S-27609+ pNeuECDTM treated-animals were free of tumours (Po0.05). As shown in Figure 3 , the simultaneous treatment with Imiquimod and pNeuECDTM plasmid resulted in no mice bearing more than two or three tumour masses in comparison with pNeuECDTM plasmid alone. Figure 4 shows the production of anti-p185 neu antibodies (top) and the Ig isotype of the antibody response against HER-2/neu (bottom). At 2 weeks after the last immunization, antibodies directed against p185 neu , the product of HER-2/neu gene, were found slightly increased in mice treated with Imiquimod or S-27609. Anti-p185 neu antibody production induced by pNeuECDTM vaccine was higher than the production of antibodies in animals treated with adjuvants alone, and was significantly increased by the simultaneous administration of either Imiquimod or S-27609 adjuvant molecules (Po0.05 versus pNeuECDTM alone) (Figure 4, top) . In the group of mice treated with Imiquimod+pNeuECDTM, antip185 neu antibodies were mainly of the IgG2a subclass, with a minor IgG1 component (Figure 4 , bottom). Sera from this group showed a significantly higher titre of IgG2a (Po0.05) and reduced levels of IgG1 (Po0.05) than those observed in mice vaccinated with pNeuECDTM alone. In the mice group treated with S27609+pNeuECDTM, the isotype of anti-p185 neu antibodies was similar to that of pNeuECDTM-treated animals. Figure 5 shows the cytotoxic activity of splenocytes obtained from treated and control mice against N202/ 1A, a rat HER2/neu-overexpressing tumour cell line. As shown in the figure, similar levels of cytotoxicity were found in control, Imiquimod-treated, and S-27609-treated mice. DNA vaccination against HER2/neu activated anti-HER-2/neu-specific lymphocyte cytotoxic activity. Cytotoxicity observed in pNeuECDTM-vaccinated mice was lightly but significantly increased by the simultaneous administration of Imiquimod, as evidenced by both cytotoxicity at different E:T cell ratios and number of Lytic Units ( Figure 5 , Po0.05).
Graphs in Figure 6 describe the production of immunomodulant cytokines 24 h (a) or 48 h (b) following in vitro stimulation of lymphocytes obtained from the spleen of treated and control mice with tumour cells overexpressing HER2/neu antigen. As shown in the figure, in vitro stimulation of cells from pNeuECDTMvaccinated mice induced a small, but significant augmentation of IFNg and IL2 production by CD8T cells with respect to cells from control mice (Po0.05). The association of Imiquimod to the vaccine lightly and significantly increased both IFNg and IL2 production by CD8T cells in comparison with pNeuECDTM vaccine alone (Po0.05). S-27609+pNeuECDTM did not significantly change the cytokine production by CD8T cells in comparison with vaccine alone. IL10 production was not changed, whereas IL-4 production was significantly reduced (Po0.02) by CD4T cells from pNeuECDTMtreated mice. In lymphocytes obtained from mice vaccinated and treated with Imiquimod, IL10 production 
Effect of adoptive transfer of sera
Since the analysis of anti-p185 neu antibodies indicated a substantial increase of antibodies with a switch from IgG1 to IgG2a phenotype in mice vaccinated and supplemented with Imiquimod, we investigated the protection afforded by the transfer of sera from Imiquimod+pNeuECDTM-treated mice in untreated FVB/neu-T female recipients. As shown in Figure 7 , transfer of sera from mice vaccinated and treated with Imiquimod provided significant inhibition, with a higher effect than with sera from mice treated with vaccine alone. No inhibition followed the transfer of serum from control unvaccinated mice.
Discussion
Various experimental studies, some of which were carried out by our group, have demonstrated that DNA vaccination represents a good methodology for activating the immune system against HER2/neu. [5] [6] [7] [8] [9] [10] [11] [12] [13] The specific stimulation of humoral and cellular immune effectors has been shown to prevent the spontaneous development of mammary tumours occurring in mice transgenic for the HER-2/neu oncogene at an early age. The combination of cytokines or immunoregulatory molecules, together with HER-2/neu-encoding DNA plasmid, increased the effectiveness of the HER-2/neu vaccine, thus providing substantial evidence for the utility of adjuvants for DNA vaccination. 5, [10] [11] [12] [13] In this study, FVB/neuT mice were vaccinated with a DNA vaccine encoding the extracellular and transmembrane HER2/neu domains through Gen gun-system delivery given alone or in combination with Imiquimod or S-27609 as adjuvants. Among various systems of DNA delivery tested in our laboratory, the Gene-gun-system did not prove to be the optimal method of DNA vaccination to hamper the development of spontaneous mammary carcinoma in FVBneuNT transgenic mice, but it was chosen as appropriate to evaluate the potential of adjuvant compounds in improving the efficacy of a DNA vaccine protocol. Our results demonstrate, for the first time, the effectiveness of Imiquimod and S-27609 as adjuvants for antitumoral DNA vaccination in a transgenic tumour model. In particular, the data show that Imiquimod and, with lower efficacy, S-27609 delayed the development and reduced the incidence of spontaneous mammary tumours, increasing both antibody and cellmediated immune responsiveness induced by a DNA vaccine against HER-2/neu.
The small molecular weight imidazoquinolines, and among these Imiquimod and its derivatives, are 14 Stimulation of endogenous cytokine levels, numerical and functional modulation of dendritic cells, binding and activation of TLR-7 and TLR-8, and boosting of perforins in cytotoxic lymphocytes are some of the mechanisms involved in the effect of Imiquimod and its derivatives. [14] [15] [16] [17] [18] [19] The positive effect of Imiquimod and its derivative resiquimod on immune responses to immunization using DNA as the vaccine agent has recently been reported. 18 Both these compounds were found to induce significant increases in cytokine production from antigen-specific T cells when administered in combination with vaccination using plasmid DNA encoding chicken ovalbumin, compared with vaccination without these adjuvants. 18 However, no data has been reported in that paper on their protective effectiveness as 
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A Smorlesi et al antitumour compounds over the effect determined by plasmid DNA vaccines. The results reported in our paper, besides agreeing with and confirming the adjuvant role of imidazoquinolines in the induction of the immune response after DNA immunization, show, for the first time, the protective role of Imiquimod and the related compound S-27609 in the prevention of spontaneous mammary carcinomas occurring in HER-2/neu transgenic mice. The effect, which was markedly more evident using Imiquimod than S-27609, consisted in a delayed development of mammary tumours, and, particularly, in a reduced incidence of these tumours, with almost 80 and 40% of tumour-free mice at 40 weeks for Imiquimod and S-27609, respectively, over the 12% of tumour-free mice found in animals receiving only the plasmid DNA.
Since the treatment with either Imiquimod or S-27609 alone resulted in no protective effect on tumour development, in our model it is evident that antitumoral activity of these molecules does not correlate with their proapoptotic activity on tumour cells that has been previously described, 20 but, rather, it was based on an immune modulation. Effectively, and in particular for Imiquimod, the antitumour protective effect exerted by the two adjuvants given with the DNA vaccine was associated with an increased induction of antibodies specific for p185 neu , the product of the HER-2/neu gene, as well as cytotoxic lymphocytes directed against HER-2/neu, as evidenced in cytotoxicity assay and intracellular cytokine staining. It should be noted that the increase of both cytotoxicity and cytokine production by lymphocytes from vaccinated and supplemented mice was significant but not impressive; this fact may be related to the high difficulty to boost specific cytotoxic immunity in transgenic mouse models, since T-cell tolerance remains a major barrier that is difficult to overcome by therapeutic vaccination. 21 16 The induction of TH1-based immune responses opens the way for the potential application of these adjuvants for DNA vaccination in those conditions in which dominant TH2-type immune responses are present, like aging animal models where a DNA vaccine containing the HER-2/neu oncogene was far less protective against tumour development than in younger animals. 22, 23 In our study, surprisingly, Imiquimod, besides the stimulation of the release of IL2 and IFNg cytokines by CD8T cells, also increased in CD4T cells the production of IL-10, a cytokine that is mainly known for its potent immunosuppressive properties. IL10, however, is a cytokine with pleiotropic effects and has been shown in some instances to paradoxically augment tumour immunity. 24 In particular, IL-10-producing CD4T cells have been demonstrated to exert antitumour effects. These CD4T cells were not reported as typical TH2 cells but, rather, they have certain characteristics of regulatory cells. 25 The exact role of IL-10-producing CD4T cells in the antitumour effectiveness of Imiquimod remains to be further elucidated. Taken together, these findings suggest that the reaction elicited by Imiquimod supplementation and pNeuECDTM plasmid administered by Gen gun was based on the induction of multiple immune defence mechanisms that included both humoral and cell-mediated immunity.
An issue in developing tumour DNA vaccines is to design protocols that can be translated from murine models to large animal models and clinical human use without losing their potency; on the contrary, the promising strategies identified by the preclinical research for tumour vaccination in healthy mice did not show an evident therapeutic effect. 26 This evidence has been related, at least in part, to the fact that as a tumour increases in size, it becomes refractory to immunotherapy, either because of the selection of antigenic variant clones, or the release of immunosuppressive factors, or the characteristics of its stroma and its new blood vessels. 27, 28 As cancer patients have to be immunized when the tumour has been already detected, the vaccine should be a more therapeutic treatment than a preventive one. Whether Imiquimod or S-27609 may show some effectiveness as adjuvants of DNA immunization in the therapy rather than in the prevention of mammary tumours was not a matter of this study. Future studies on this topic are required which have to take into account the discrepancies between the excellent results obtained in preclinical models using HER-2/neu-based vaccines and the disappointing results that have emerged from clinical trials of therapeutic antitumour vaccines. Imiquimod and S-27609 as adjuvants of DNA vaccination A Smorlesi et al Anyway, the evidence that both Imiquimod and S-27609 improve the effectiveness of anti-HER-2/neu DNA vaccines in preventing spontaneous mammary carcinomas in transgenic mice suggest that both imidazoquinolines may be suitable adjuvants for therapeutic antitumour immunopreventive approaches.
Materials and methods
Animals FVB/N transgenic female mice for the activated rat neu oncogene were obtained from Charles River (Hollister, CA, USA) and maintained under specific pathogen-free conditions and under standard light/dark regimen (12 h light:12 h darkness) in our animal facilities. Mice were housed in plastic nongalvanized cages (4-6 mice per cage) and fed with standard pellet food (Nossan, Italy) and tap water 'ad libitum'. FVB/neu-T female mice, 8 weeks old, were used to set up experiments.
Preparation of imidazoquinolines
Imiquimod and S-27609 were kindly provided by 3M Pharmaceuticals. Both compounds were dissolved in 0.2% DMSO and water until final concentration.
Plasmid DNA and immunization protocol
The plasmid pNeuECDTM encoding extracellular and transmembrane HER2/neu regions under the control of CMV eucaryotic promoter has been kindly provided by Dr Augusto Amici from the Camerino University. Largescale preparation of plasmid DNA was carried out by Giga kit (Quiagen), according to the manufacturer's instructions. Animal immunization with DNA vaccine was performed by particle-mediated immunotherapeutic delivery using a Gene-gun system (Bio-Rad). The animals were routinely immunized by three administrations carried out at 8, 10, and 12 weeks. At every vaccination, 2 mg DNA/animal (two Gene-gun shots) were injected following a standardized protocol. pNeuECDTM vaccine was administered alone or in association with Imiquimod or S-27609; control groups included animals treated with Imiquimod or S-27609 alone, and untreated mice. Untreated mice were used as controls since experiments previously performed in our laboratory showed no difference between untreated and mock vector-vaccinated animals. To combine the antitumoral effect of the two compounds with the ability of pNeuECDTM DNA vaccine to induce an immune response against HER2/neu-overexpressing mammary carcinomas in FVBneuNT mice, we designed a protocol where mice were treated with Imiquimod or S-27609 along the time of Gene-gun immunization regimen so that the immune-stimulatory potential of the two substances was carried on during the activation of the immune response by pNeuECDTM DNA vaccine. Animals treated with Imiquimod and S-27609 received, intraperitoneally, 0.06 mg/kg of the drug in 200 ml H 2 O at every administration; animals were treated once every 3 days during the period of immunization starting 2 days before the first DNA injection.
In vivo evaluation of tumour growth
The incidence and growth of tumours were evaluated twice weekly by measuring for 60 days neoplastic masses with calipers in the two perpendicular diameters. Mice with no evidence of tumour at the end of this period were classified as tumour-free, whereas mice with a tumour 43 mm mean diameter were classified as tumour bearers. The mean number of palpable mammary carcinomas per mouse was calculated as cumulative number of incident tumours/total number of mice. All mice bearing neoplastic masses exceeding 10 mm mean diameter were killed for humane reasons.
Preparation and culture conditions of spleen cells
At 2 weeks after the last immunization, several mice were killed for immunological assays. The spleen was teased through a 60-mesh sieve in Ca 2+ and Mg
2+
-free phosphate-buffered saline (PBS, GIBCO, Gaithersburg, MD, USA) solution. Spleen cells were then fractionated on lympholyte M (Cedarlane, Canada) and mononuclear cells were separated by density gradient centrifugation (500 g, 20 min.). Cells from the interface of the gradients were washed twice with PBS and suspended in RPMI 1640 containing penicillin (100 U/ml) and streptomycin (100 mg/ml).
Cytotoxic assay
Splenocytes obtained from mice spleen were incubated at 371C and 5% CO 2 in RPMI medium containing 10% FCS in the presence of mitomycin-treated N202-1A tumour cells (60 mg/ml of mitomycin-C, Mit-C, Sigma, for 30 min at 371C) as stimulators (20:1 ratio stimulators:lymphocytes) for 5 days. N202/1A is a tumour cell line established in vitro from a carcinoma that spontaneously arose in FVB mice (202) carrying the rat HER-2/neu proto-oncogene and was found to express high levels of p185 neu . 29 Cytotoxic assay was performed using a fluorimetric method as previously reported. 30 Briefly, a stock solution of carboxyfluorescein diacetate (c'FDA, Molecular Probes, OR, USA) (20 mg/ml acetone, stored at À201C) was diluted in PBS to give a final concentration of 75 mg/ml. N202/1A tumour cells were washed twice with PBS and then labelled with c'FDA by resuspending the cells in 1 ml working solution and incubating at 371C in a humidified, 5% CO 2 incubator for 30 min. Target cells were then washed three times in PBS containing 1% BSA (Sigma) and suspended in RPMI+10% FCS at a concentration of 1 Â 10 5 /ml. 1 Â 10 4 c'FDA-labelled tumour target cells were incubated with effector spleen cells in 200 ml total volume in 96-well round microtitre plates (Nunc, Roskilde, Denmark). Effector:target cell ratios from 100:1 to 12.5:1 were tested in triplicate. The plates were kept at 371C in a humidified, 5% CO 2 incubator for 3 h and then centrifuged at 700 g for 5 min. The supernatant was separated from the cellular fraction by rapidly inverting the plate and flicking the supernatants out. Then, 100 ml of 1% Triton X100 in 0.05 M borate buffer, pH 9.0, was added to each well. The plate was kept for 20 h at 41C to allow for solubilization and then was read for fluorescence with a 1420 VICTOR were calculated by using a computational method. 31 One LU corresponded to the number of effector cells required to produce 20% of specific lysis.
Cytofluorimetric evaluation of anti-rat p185 neu antibodies At 2 weeks after the end of immunization, sera and spleens were harvested from control and experimental animals. Sera were stored at À801C and successively analysed through a cytofluorimetric assay in order to assess the presence of antibodies against HER2/neu antigen and evaluate the induction of an antigen-specific humoral immunity.
The ability of sera to bind p185 neu was evaluated by flow cytometry. 2 Â 10 5 N202/1A cells were washed twice with cold PBS, supplemented with 2% BSA and 0.05% sodium azide. Cells were then stained in a standard indirect immunofluorescence procedure with 50 ml of 1:10 dilution in PBS-azide-BSA of control or immune sera. A fluorescein-conjugated rabbit antimouse Ig (Calbiochem) or anti-mouse IgG1, anti-mouse IgG3, anti-mouse anti-mouse IgG2a, and anti-mouse IgG2b (Caltag Laboratories) were used as second-step Ab. The cells were resuspended in Isoton II (Coulter, Hialeah, FL, USA) and evaluated through a Coulter XL flow cytometer. The specific N202-1A-binding potential (Sbp) of the sera was calculated as follows: ((% positive cells with test serum) (fluorescence mean))À((% positive cells with control serum) (fluorescence mean)) Â serum dilution, as previously described in detail. 32 
Intracellular cytokine staining
Splenocytes obtained from mice spleen were incubated overnight at 371C and 5% CO 2 in RPMI medium containing 10% FCS in the presence of mitomycin-treated N202-1A tumour cells as stimulators (20:1 ratio of stimulators:lymphocytes); cells were harvested and stained in PBS buffer containing 5% FCS and 0.01% NaN 3 , with anti-CD4 or anti-CD8 monoclonal antibodies (BD Pharmingen) PE-conjugated; cells were then fixed in 0.2% formaline, successively stained in a PBS buffer containing 5% FCS and 0.05% NaN 3 with anti-IL10, anti-IL2, or anti-IFNg (BD Pharmingen) FITC-conjugated, and finally analysed by a Coulter XL flow cytometer.
Adoptive transfer of sera
In order to test the capacity of anti-p185 neu sera to interfere with the development of p185 neu -overexpressing tumour cells, 2-month-old FVBneuT female mice received sera from treated and control mice. In total, 150 ml of pooled sera of mice belonging to each one of the treatment groups was injected intraperitoneally in each animal (five animals/treatment sera). At 24 h after the treatment with sera, mice were s.c. challenged with 10 5 N202/1A tumour cells and successively monitored to register the kinetic of development of injected tumours.
Statistical analysis
Differences in tumour incidence were evaluated by the Mantel-Haenszel log-rank test; differences in tumour multiplicity were evaluated by Student's t-test. Differences in immune parameters were evaluated by ANOVA followed by the Student-Newman-Keuls post hoc test when appropriate. Differences were considered statistically significant when Po0.05.
